Ref21C13 - Therapeutic effect of Siliphos® in chronic liver disease
Therapeutic and Antilipoperoxidant Effects of Silibyn-Phosphatidylcholine Complex (Siliphos®) in Chronic Liver Disease:
S. Moscarella1, A. Giusti1, F. Marra1, C. Marena2, M. Lampertico2, P. Relli1, P. Gentilini1 and G. Buzzelli1
Institute of Clinica Medica II, University of Florence, Florence, Italy and 2Medical Department, Inverna della Beffa, Milan, Italy
Journal not listed on Medline
Eight patients (two men and six women), with viral chronic active hepatitis were treated with (Siliphos®) for two months. After treatment, serum malondialdehyde levels decreased by 36% (which indicates significantly less liver damage) and the quantitiative liver function evaluation increased by 15% (which is quite dramatic). A statistically significant reduction of transaminases was also seen. These results indicate (Siliphos®) is effective in improving the biochemical and quantitative indices of hepatic function in patients with chronic active hepatitis.